Paradigm Biopharmaceuticals (ASX:PAR) Cash-to-Debt : 115.69 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Paradigm Biopharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 115.69.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Paradigm Biopharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Paradigm Biopharmaceuticals's Cash-to-Debt or its related term are showing as below:

ASX:PAR' s Cash-to-Debt Range Over the Past 10 Years
Min: 64.3 Med: 215.2 Max: No Debt
Current: 115.69

During the past 8 years, Paradigm Biopharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 64.30. And the median was 215.20.

ASX:PAR's Cash-to-Debt is ranked better than
79.74% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs ASX:PAR: 115.69

Paradigm Biopharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Paradigm Biopharmaceuticals Cash-to-Debt Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

118.90

94.46

64.30

164.72

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial												92.49	64.30	215.20	164.72	115.69

Competitive Comparison of Paradigm Biopharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Cash-to-Debt falls into.

Paradigm Biopharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Paradigm Biopharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	56.333	/	(0.105	+	0.237)
	=	164.72

Paradigm Biopharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	33.551	/	(0.113	+	0.177)
	=	115.69

Paradigm Biopharmaceuticals (ASX:PAR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Paradigm Biopharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PBIGF:USA

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).